GlassScriptPhysician profile
Ashley Thurman
NPI 1629207071
$5,264.20
in general payments reported to CMS, 2019-2025
27 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.61 · 2022: $481 · 2023: $1,621 · 2024: $1,463 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,268 · Education: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,268.29 |
| Education | $416.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $692.54 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $620.25 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $589.57 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $572.86 | 2021-2025 | |
| Janssen Biotech, INC. | $466.12 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $413.94 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $363.91 | 2023-2025 | |
| Ucb, INC. | $232.65 | 2022-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $201.22 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $189.04 | 2023-2025 | |
| Amgen INC. | $140.79 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $126.89 | 2023-2025 | Sotyktu |
| Incyte Corporation | $116.48 | 2022-2025 | Opzelura |
| Organogenesis INC. | $85.43 | 2024-2025 | Novachor |
| Galderma Laboratories, L.P. | $62.02 | 2025 | Nemluvio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $59.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.23 | 2023-2024 | Spevigo |
| Organon LLC | $53.53 | 2025 | Vtama |
| Mallinckrodt Hospital Products INC. | $47.41 | 2024-2025 | Acthar |
| Biofrontera INC. | $39.37 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Almirall LLC | $25.71 | 2025 | Seysara |
| Acclarent, INC | $24.04 | 2023 | Acclarent Aera |
| Botanix Sb INC | $20.70 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $19.07 | 2024 | Ycanth |
| Genentech USA, INC. | $15.35 | 2024 | Erivedge |
| Arcutis Biotherapeutics, INC. | $14.74 | 2023 | |
| Dermavant Sciences, INC. | $13.35 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Thurman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.